Skip to main content
    X

    Xeris Pharmaceuticals Inc (XERS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $16.70
    +0.04 (+0.24%)

    Market Cap: $3.04B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Xeris Pharmaceuticals Inc (XERS) P/E Ratio & Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Xeris Pharmaceuticals (XERS) trades at 139.2x trailing earnings and 8.2x sales. Its P/S of 8.2x is above its 5-year median of 2.7x. Its forward P/E is 85.5x. The median P/E across 11 similar companies is 10.7x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 62.8% higher over the next year.

    MultipleValue
    P/E (trailing)139.2x
    Forward P/E85.5x
    Price to sales8.2x
    Price to book61.9x
    EV/EBITDA48.8x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 100.0% above 4.1x.

    MultipleCurrent5-year median10-year median
    P/S8.2x2.7x4.1x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 101 months (10-year).

    Valuation History

    Over the 8 year ends shown, its P/S ranged from 1.6x in 2022 to 68.1x in 2019.

    Year endPriceP/SP/B
    2025$7.854.4x103.3x
    2024$3.392.5xN/A
    2023$2.352.0xN/A
    2022$1.331.6x4.0x
    2021$2.934.8x3.8x
    2020$4.9211.0x7.8x
    2019$7.0568.1x13.2x
    2018$17.0044.6x4.7x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About XERS

    What is XERS's forward P/E ratio?

    Xeris Pharmaceuticals has a forward P/E ratio of 85.5x.

    Is XERS stock overvalued?

    GNG's valuation label for XERS is Overvalued. Its P/E of 139.2x compares with a median of 10.7x across 11 similar companies.

    What is XERS's price to sales ratio?

    Xeris Pharmaceuticals has a price to sales ratio of 8.2x.